The world\u2019s first lung cancer vaccine, known as CIMAvax-EGF, has entered clinical trials in seven countries, marking a major milestone in cancer treatment.<\/p>\n
Unlike preventive vaccines, this is a therapeutic vaccine designed to treat existing lung cancer by targeting and neutralizing epidermal growth factor (EGF) \u2014 a protein that promotes the growth of cancer cells.<\/p>\n
Developed in Cuba, the vaccine has already shown promising results in extending survival for patients with advanced non-small cell lung cancer (NSCLC).<\/p>\n
Now, international clinical trials are being launched in the United States, United Kingdom, Japan, Cuba, Serbia, Bosnia and Herzegovina, and Colombia.<\/p>\n
The U.S. trials are being led by Roswell Park Comprehensive Cancer Center in partnership with Cuban researchers.<\/p>\n
This groundbreaking collaboration could offer a new path forward in cancer immunotherapy, particularly for one of the deadliest cancers globally.<\/p>\n
If successful, the vaccine may significantly improve outcomes and quality of life for lung cancer patients around the world.<\/p>\n
. Science pulse<\/p>\n
<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
The world\u2019s first lung cancer vaccine, known as CIMAvax-EGF, has entered clinical trials in seven countries, marking a major milestone in cancer treatment. Unlike preventive vaccines, this is a therapeutic vaccine designed to treat existing lung cancer by targeting and neutralizing epidermal growth factor (EGF) \u2014 a protein that promotes the growth of cancer cells. Developed in Cuba, the vaccine has already shown promising results in extending survival for patients with advanced non-small cell lung cancer (NSCLC). Now, international clinical trials are being launched in the United States, United Kingdom,<\/p>\n","protected":false},"author":3,"featured_media":14193,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18,11,20],"tags":[],"class_list":["post-14192","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-english","category-11","category-20"],"_links":{"self":[{"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/posts\/14192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/USBnews24.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14192"}],"version-history":[{"count":1,"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/posts\/14192\/revisions"}],"predecessor-version":[{"id":14194,"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/posts\/14192\/revisions\/14194"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/USBnews24.com\/index.php?rest_route=\/wp\/v2\/media\/14193"}],"wp:attachment":[{"href":"https:\/\/USBnews24.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/USBnews24.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/USBnews24.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}